Abstract
Eribulin mesylate, a synthetic analogue of halichondrin B, exhibits anti-tumor effects through a unique cytotoxic and non-cyctotoxic actions. In landmark phase-3 EMBRACE trial, eribulin showed promising beneficial outcomes in the treatment of locally advanced or metastatic breast cancer (LA/MBC). A limited number of Asian subset of the population were involved in the previous trials. Here, we report the safety and efficacy of eribulin in Indian patients with LA/MBC from a post marketing phase IV study.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
